Yanyun Zhao

Yanyun Zhao

Auto-generated profile, based on publicly available information

Yanyun Zhao

Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
XSXiaoyu Sun
Xiaoyu Sun
XLXuemei Lv
Xuemei Lv
YYYuanyuan Yan
Yuanyuan Yan
YZYanyun Zhao
Yanyun Zhao
RMRong Ma
Rong Ma
MWMinjie Wei
Minjie Wei
Drug resistance is a major obstacle in the treatment of tumors, which easily lead to relapse or poor prognosis. Cancer stem cells (CSCs) are regarded as one of the important targets that mediate tumor resistance. Increasing evidence shows that the tumor hypoxia microenvironment is closely related to the resistance of CSCs to chemotherapy and radiotherapy. In this review, we intend to review the articles that have described how the hypoxic microenvironment affects CSC stemness and mediates tumor resistance and provide new directions and methods in the clinical treatment of tumors. Here, we also discuss the feasibility and development prospects of using hypoxia-inducible factors (HIFs) that regulate the hypoxic microenvironment of tumors as targeted agents to treat tumors, as well as to reduce or even reverse the resistance of tumors to chemotherapy and radiotherapy.

28 June 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
XLXuemei Lv
Xuemei Lv
MHMiao He
Miao He
YZYanyun Zhao
Yanyun Zhao
LZLiwen Zhang
Liwen Zhang
WZWenjing Zhu
Wenjing Zhu
MWMinjie Wei
Minjie Wei
Triple negative breast cancer (TNBC) is a specific subtype of breast cancer with a poor prognosis due to its aggressive biological behaviour and lack of therapeutic targets. We aimed to explore some novel genes and pathways related to TNBC prognosis through bioinformatics methods as well as potential initiation and progression mechanisms. Breast cancer mRNA data were obtained from The Cancer Genome Atlas database (TCGA). Differential expression analysis of cancer and adjacent cancer, as well as, triple negative breast cancer and non-triple negative breast cancer were performed using R software. The key genes related to the pathogenesis were identified by functional and pathway enrichment analysis and protein–protein interaction network analysis. Based on univariate and multivariate Cox proportional hazards model analyses, a gene signature was established to predict overall survival. Receiver operating characteristic curve was used to evaluate the prognostic performance of our model. Based on mRNA expression profiling of breast cancer patients from the TCGA database, 755 differentially expressed overlapping mRNAs were detected between TNBC/non-TNBC samples and normal tissue. We found eight hub genes associated with the cell cycle pathway highly expressed in TNBC. Additionally, a novel six-gene (TMEM252, PRB2, SMCO1, IVL, SMR3B and COL9A3) signature from the 755 differentially expressed mRNAs was constructed and significantly associated with prognosis as an independent prognostic signature. TNBC patients with high-risk scores based on the expression of the 6-mRNAs had significantly shorter survival times compared to patients with low-risk scores (P < 0.0001). The eight hub genes we identified might be tightly correlated with TNBC pathogenesis. The 6-mRNA signature established might act as an independent biomarker with a potentially good performance in predicting overall survival.

21 October 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LZLiwen Zhang
Liwen Zhang
MHMiao He
Miao He
WZWenjing Zhu
Wenjing Zhu
XLXuemei Lv
Xuemei Lv
YZYanyun Zhao
Yanyun Zhao
MWMinjie Wei
Minjie Wei

30 December 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
RMRong Ma
Rong Ma
YZYanyun Zhao
Yanyun Zhao
MHMiao He
Miao He
HZHongliang Zhao
Hongliang Zhao
YZYifan Zhang
Yifan Zhang
MWMinjie Wei
Minjie Wei
Background: Increasing studies have suggested that aberrant expression of microRNAs might play essential roles in the progression of cancers. In this study, we sought to construct a high-specific and superior microRNAs signature to improve the survival prediction of colon adenocarcinoma (COAD) patients. Methods: The genome-wide miRNAs, mRNA and lncRNA expression profiles and corresponding clinical information of COAD were collected from the TCGA database. Differential expression analysis, Kaplan–Meier curve and time-dependent ROC curve were calculated and performed using R software and GraphPad Prism7. Univariate and multivariate Cox analysis was performed to evaluate the prognostic ability of signature. Functional enrichment analysis was analyzed using STRING database. Results: We identified ten prognosis-related microRNAs, including seven risky factors (hsa-miR-197, hsa-miR-32, hsa-miR-887, hsa-miR-3199-2, hsa-miR-4999, hsa-miR-561, hsa-miR-210) and three protective factors (hsa-miR-3917, hsa-miR-3189, hsa-miR-6854). The Kaplan–Meier survival analysis showed that the patients with high risk score had shorter overall survival (OS) in test series. And the similar results were observed in both validation and entire series. The time-dependent ROC curve suggested this signature have high accuracy of OS for COAD. The Multivariate Cox regression analysis and stratification analysis suggested that the ten-microRNA signature was an independent factor after being adjusted with other clinical characteristics. In addition, we also found microRNA signature have higher AUC than other signature. Furthermore, we identified some miRNA-target genes that affect lymphatic metastasis and invasion of COAD patients. Conclusion: In this study, we established a ten-microRNA signature as a potentially reliable and independent biomarker for survival prediction of COAD patients.

20 March 2023 in Molecules
Verified
Journal Article
Open access
PDF file
HLHongyuan Lu
Hongyuan Lu
QWQinbiao Wang
Qinbiao Wang
XJXiaowen Jiang
Xiaowen Jiang
YZYanyun Zhao
Yanyun Zhao
MHMiao He
Miao He
MWMinjie Wei
Minjie Wei
Cannabidiol (CBD) is the main active ingredient in the cannabis plant used for treating epilepsy and related diseases. However, how CBD ameliorates epilepsy and its effect on the hippocampus remains unknown. Herein, we evaluated how CBD ameliorates seizure degree in pentylenetetrazol (PTZ) induced epilepsy mice after being exposed to CBD (10 mg/kg p.o). In addition, transcriptome and metabolomic analysis were performed on the hippocampus. Our results suggested that CBD could alleviate PTZ-induced seizure, of which the NPTX2, Gprc5c, Lipg, and Stc2 genes were significantly down-regulated in mice after being exposed to PTZ. Transcriptome analysis showed 97 differently expressed genes (CBD) and the PTZ groups. Metabonomic analysis revealed that compared with the PTZ group, 41 up-regulated and 67 down-regulated metabolites were identified in the hippocampus of epileptic mice exposed to CBD. The correlation analysis for transcriptome and metabolome showed that (±) 15-HETE and carnitine C6:0 were at the core of the network and were involved in the positive or negative regulation of the related genes after being treated with CBD. In conclusion, CBD ameliorates epilepsy by acting on the metabolism, calcium signaling pathway, and tuberculosis pathways in the hippocampus. Our study provided a practical basis for the therapeutic potential of treating epilepsy using CBD.

21 October 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
XLXuemei Lv
Xuemei Lv
YZYanyun Zhao
Yanyun Zhao
LZLiwen Zhang
Liwen Zhang
SZShuqi Zhou
Shuqi Zhou
BZBing Zhang
Bing Zhang
MHMiao He
Miao He